{"entity":{"id":"halda-therapeutics","kind":"company","name":"Halda Therapeutics","aka":[],"tldr":"Halda Therapeutics invented a new kind of oral cancer drug that links a protein found only in tumour cells to a protein cells need to survive, killing the cancer cell. Johnson & Johnson bought the company for 3.05 billion US dollars in 2025.","summary":"Halda Therapeutics was a New Haven, Connecticut clinical-stage biotechnology company built on its Regulated Induced Proximity Targeting Chimera (RIPTAC) platform: heterobifunctional oral molecules that bring a tumour-specific protein together with a protein essential for cell survival, producing a hold-and-kill mechanism intended to overcome resistance to existing targeted therapies. Its lead candidate, HLD-0915, is a once-daily oral therapy in clinical development for prostate cancer, and the platform is being applied to other solid tumours. SEC Form D filings show about 41 million US dollars sold in 2021 and roughly 150 million US dollars sold across two 2024 offerings. Johnson & Johnson completed its acquisition of Halda for 3.05 billion US dollars in cash on 29 December 2025; the Halda website now redirects to J&J Innovative Medicine.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.haldatx.com/"},{"label":"J&J completion press release","url":"https://www.jnj.com/media-center/press-releases/johnson-johnson-completes-acquisition-of-halda-therapeutics-and-its-novel-platform-to-revolutionize-cancer-treatment-and-enable-next-generation-oral-therapies"},{"label":"J&J Q4 2025 results referencing the acquisition (SEC exhibit)","url":"https://www.sec.gov/Archives/edgar/data/200406/000020040626000002/a2025q4exhibit991.htm"}],"tags":[],"related":[],"cancers":["prostate"],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["haldatx.com redirects to a J&J page that showed a site-maintenance notice, so no original company page was available. The 2024 Form D offerings are widely reported as the Series B but that label was not verified. HLD-0915's clinical phase was not stated in the fetched release beyond 'clinical-stage'."],"hq":"New Haven, CT","country":"US","companyType":"biotech","website":"https://www.haldatx.com/","founded":2018,"stage":"acquired","investors":[],"funding":[{"round":"Form D offering","year":2021,"amountUsd":40990001,"source":"https://www.sec.gov/Archives/edgar/data/1769401/000176940121000001/primary_doc.xml","note":"Total sold of a 51 million US dollar offering per Form D filed December 2021"},{"round":"Form D offering","year":2024,"amountUsd":24211678,"source":"https://www.sec.gov/Archives/edgar/data/1769401/000176940124000001/primary_doc.xml","note":"Total sold of a 36 million US dollar offering per Form D filed May 2024"},{"round":"Form D offering","year":2024,"amountUsd":126471316,"source":"https://www.sec.gov/Archives/edgar/data/1769401/000176940124000002/primary_doc.xml","note":"Total sold per Form D filed August 2024"},{"round":"Acquisition","year":2025,"amountUsd":3050000000,"source":"https://www.jnj.com/media-center/press-releases/johnson-johnson-completes-acquisition-of-halda-therapeutics-and-its-novel-platform-to-revolutionize-cancer-treatment-and-enable-next-generation-oral-therapies","note":"3.05 billion US dollars in cash; completion announced 29 December 2025"}],"acquiredBy":"johnson-johnson"},"route":"/companies/halda-therapeutics/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"company":[{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","route":"/companies/johnson-johnson/"},{"id":"vida-ventures","kind":"company","name":"Vida Ventures","route":"/companies/vida-ventures/"}]}}